

June 10, 2009.

**UPPER
PENINSULA
REGIONAL
REFERENCE
LABORATORY**

David Graser
Chief Information
Officer

John D. Weiss, MD
Medical Director

John M. Rhoades
Laboratory
Program Director

888-818-3879

906-225-3050

FAX: 906-225-3849

Dear Physicians, Reference Lab Clients, and Clinics;


Marquette General Laboratory is pleased to announce the availability of Urovysion Bladder Cancer FISH testing through our Cytogenetics Laboratory.

Urovysion[®] is the first FDA-approved genomic DNA-probe test that directly reveals the chromosomal abnormalities associated with bladder cancer. Urovysion[®] aids in the initial diagnosis of bladder carcinoma in patients with hematuria and assists with the subsequent monitoring of tumor recurrence in patient's previously diagnosed with bladder cancer. Urovysion[®] also serves to appropriately heighten clinical suspicions and increase surveillance efforts in patients with negative cytology / cystoscopy. Urovysion[®] is a highly accurate companion test that, when paired with cytology and cystoscopic examination, provides unequivocal results that significantly improve patient survivability and care.

Urovysion[®] testing requires a minimum of 50 ML of urine, with the ideal specimen being the second clean catch urine of the day. Refrigeration and shipment at temperatures up to 25°C within 24 hours of collection is required. Shipment on ice is preferred. For additional information regarding Urovysion[®] testing or to obtain Urovysion[®] collection kits, please contact the MGHS Laboratory at (906) 225-3050 or toll-free @ (888) 818-3879 and ask for client services or visit our web catalog for more information.

<http://www.mgh.org/lab/CATALOG/TESTS/5768.HTM>

Sincerely,



John M. Rhoades, MPA, MT(ASCP)
Laboratory Program Director
Marquette General Health System Laboratory
jrhoades@mgh.org